Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review

Table 3 Mean scores of pain measured by VAS

Author	No. of patients	Mean baseline (SD)	Mean end point (SD)	Mean change vs. baseline	Mean % change vs. baseline
Wu et al. [56] placebo
week 1	20	6.9(2.3)	4.5	2.4	35
week 4	20	6.9(2.3)	4.7	2.2	32
week 8	20	6.9(2.3)	5.1	2.2	26
week 12	20	6.9(2.3)	5.3	1.6	23
Wu et al. [56] BTX-A
week 1	22	7.1(2.0)	4.2	2.9	41
week 4	22	7.1(2.0)	2.4	4.7	66^a
week 8	22	7.1(2.0)	1.4	5.7	80^a
week 12	22	7.1(2.0)	1.4	5.7	80^a
Bohluli et al. [57]
week 1	15	8(1.9)	1.5(1.7)	6.5	81^b
month 1	15	8(1.9)	1.2(1.4)	6.8	85^b
Türk et al. [59]
week 1	8	Unclear	Unclear	Unclear	Unclear^b
month 2	8	Unclear	Unclear	Unclear	Unclear^b
month 6	8	Unclear	Unclear	Unclear	Unclear^b
Piovesan et al. [51] ^c
day 10	13	9.9(0.3)	5.0(3.9)	4.9	49^b
day 20	13	9.9(0.3)	0.5(2.0)	9.4	95^b
day 30	13	9.9(0.3)	0.2(1.0)	9.7	98^b
day 60	13	9.9(0.3)	2.2(2.9)	7.7	78^b

ISSN: 1129-2377